Esperion Prices Upsized $70M IPO for Statin Alternative Work
Following in the footsteps of upsized initial public offerings (IPOs) from PTC Therapeutics Inc. and Bluebird Bio, Plymouth, Mich.-based Esperion Therapeutics Inc. priced an IPO to raise $70 million – $80.5 million if underwriters exercise overallotments in full – to support midstage testing of its lead compound, ETC-1002, as an alternative to statin therapy in lowering LDL-cholesterol (LDL-C).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST